R. Adinin

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris et al. · Journal of Clinical Oncology · 2009 · 486 citations · Full text

A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin

Kamalesh K. Sankhala, Akira Mita, R. Adinin et al. · Journal of Clinical Oncology · 2009 · 81 citations

Lipid Preparation, Tumor Biology, Pharmaceutical Science +15

Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)

M. C. Green, Lajos Pusztai, R. Theriault et al. · Journal of Clinical Oncology · 2006 · 31 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +15

Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC)

Scott Kopetz, James L. Abbruzzese, Cathy Eng et al. · Journal of Clinical Oncology · 2006 · 22 citations

Phase Ii Study, Pharmacotherapy, Pre-clinical Pharmacology +19

Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer

Scott Kopetz, K. Y. Glover, Cathy Eng et al. · Journal of Clinical Oncology · 2007 · 10 citations

Phase Ii Study, First-line Treatment, Pharmacotherapy +18